Results 1 to 10 of about 49,496 (199)
Sustained Release Antiparkinson Agents: Controlled Release Levodopa [PDF]
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1992 ABSTRACT:The rationale for sustained release oral levodopa preparations is to deliver levodopa in the areas of maximal intestinal absorption in a slow and predictable way, leading to stable plasma levodopa levels and brain dopamine levels, therefore resulting in a lengthened duration of action.
Serge Gauthier, Donna Amyot
+6 more sources
Anticonvulsant Activity of Antiparkinsonism Agents
Experimental Biology and Medicine, 1968 SummaryThe anticonvulsant activity of synthetic antiparkinsonism agents has been studied in mice with experimental seizures and in children with myoclonic spasms refractory to conventional medications. Procyclidine and trihexyphenidyl protected mice from maximal electroshock seizures.
J Gordon Millichap +2 more
openaire +4 more sources
Association between Parkinson’s disease and cardiovascular disease mortality: a prospective population-based study from NHANES [PDF]
Lipids in Health and DiseaseBackground and aim Conflicting results have been reported on the association between Parkinson's disease (PD) and cardiovascular disease (CVD) mortality in different populations.
Li Ke +3 more
doaj +2 more sources
Impact of insufficient drug efficacy of antiparkinson agents on patient's quality of life: a cross-sectional study. [PDF]
BMC Neurol, 2015 Tsugawa J +5 more
europepmc +3 more sources
COMPARISON OF THE ELECTROENCEPHALOGRAPHIC AND MOTOR EFFECTS OF ORPHENADRINE, AN ANTIPARKINSON AGENT
Japanese Journal of Pharmacology, 1968 Takashi Ban, Masakazu Hojo
openaire +5 more sources
2. Neuromuscular Disorders due to Adverse Effects of Antiparkinson Agents
Nihon Naika Gakkai Zasshi, 2007 Nobutaka Hattori
openaire +5 more sources
Characteristic action of BAM-1110, a new antiparkinson agent, on dopamine receptors
Japanese Journal of Pharmacology, 1997 Mitsuaki Nagasaka +3 more
openaire +3 more sources
Validation of 19-items wearing-off (WOQ-19) questionnaire to Portuguese [PDF]
Arquivos de Neuro-Psiquiatria, 2020 Background: The treatment of Parkinson disease with dopaminergic therapy improves functionality and quality of life. However, as the disease progresses, the wearing-off phenomenon develops.
Carlos Eduardo MANTESE +3 more
doaj +1 more source
Arquivos de Neuro-Psiquiatria, 2022 The treatment of Parkinson's disease (PD) is challenging, especially since it is considered highly individualized. The Brazilian Academy of Neurology has recognized the need to disseminate knowledge about the management of PD treatment, adapting the best
Roberta Arb Saba +21 more
doaj +1 more source